(Total Views: 507)
Posted On: 02/19/2021 12:53:30 PM
Post# of 153986
Re: Cassandra X #78686
Share price "drifts" downwards?
Only due to shorts shorting and instilling fear into new or weak/kneed investors.
Nader "over-promises". Absolutely not. He has never "promised" anything. Regardless what you think of him, he ain't that dumb, Come On Man! He is over-optimistic about timelines, which are of course out of his control. And some timelines may have been missed, due to fishy influences, who knows.
The bottom line is yes we are due for results, but not overdue to the point of concern. And I certainly agree that the silence is "probably" an indicator of good news, and we have generally always had confidence in s/c data be good or great or better.
I remain with being 4% doubtful, because I don't trust any gov't agency, including the FDA. My sister, a pharma lobbyist says "no way, the FDA is not in the least corrupt". Hmm.
As delays extend, it appears some investors are entering the "grey area" as to whether the FDA may be influenced to delay or deny leronlimab. I say there's a 4% to 8% chance of yes. However, that is the only issue that concerns me, not competition nor our s/c trial data results.
Only due to shorts shorting and instilling fear into new or weak/kneed investors.
Nader "over-promises". Absolutely not. He has never "promised" anything. Regardless what you think of him, he ain't that dumb, Come On Man! He is over-optimistic about timelines, which are of course out of his control. And some timelines may have been missed, due to fishy influences, who knows.
The bottom line is yes we are due for results, but not overdue to the point of concern. And I certainly agree that the silence is "probably" an indicator of good news, and we have generally always had confidence in s/c data be good or great or better.
I remain with being 4% doubtful, because I don't trust any gov't agency, including the FDA. My sister, a pharma lobbyist says "no way, the FDA is not in the least corrupt". Hmm.
As delays extend, it appears some investors are entering the "grey area" as to whether the FDA may be influenced to delay or deny leronlimab. I say there's a 4% to 8% chance of yes. However, that is the only issue that concerns me, not competition nor our s/c trial data results.
(5)
(0)
